Figure 2 from Enfortumab Vedotin plus Pembrolizumab as First-line Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Results from EV-202 Cohort 9
Year: 2026
Type: other
Abstract: Efficacy per investigator assessment. A, Best change from baseline in the size of the target lesion. B, Time to response and DOR in patients with confirmed responses. C, Kaplan–Meier plots of PFS. N/A, not applicable; PD, progressive disease; SD, stable disease.
Authors: Paul L. Swiecicki, Glenn J. Hanna, Jessica L. Geiger, Takao Fujisawa, Missak Haigentz, Yoshitaka Honma, Justine Y. Bruce, Kaoru Tanaka, Kei Muro, Priyanka Bhateja, Jason Kaplan, Shubin Liu, Seema Gorla, Michele Wozniak, Ryan Dillon, Salaheldin Hamed, Changting Meng, Marya F. Chaney, Ari J. Rosenberg
Topic: Head and Neck Cancer Studies
Subfield: Otorhinolaryngology
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W7203499351
Cites:
Cited by:
Related to: